Gene polymorphisms of epidermal growth factor receptor and its downstream effector, interleukin-8, predict oxaliplatin efficacy in patients with advanced colorectal cancer.

摘要: Abstract Background Researchers have recently reported an association between the epidermal growth factor receptor (EGFR) pathway and platinum-chemotherapy sensitivity in cancer patients. The (CA) n repeat polymorphism intron 1 of EGFR gene has been identified found to alter expression vitro as well vivo. A higher number these CA repeats is associated with lower levels, whereas a low levels. second key within (HER1 R497K) single nucleotide change (G→A) codon 497 gene, which leads arginine→lysine substitution extracellular domain subdomain IV. Furthermore, interleukin-8 (IL-8), downstream effector, plays vital role tumor angiogenesis progression. Three other polymorphisms, each related IL-8 also playing pivotal pathway: T-251A promoter region G+2607C exon 2 CXCR1 C+785T 11 CXCR2 gene. Patients Methods In this study, we employed 5′-end 33P-γATP–labeled polymerase chain reaction (PCR) protocol PCR–restriction fragment length method order determine genotypes for previously mentioned polymorphisms 105 patients metastatic colorectal cancer. Tests were conducted establish whether could predict clinical outcome 5-flourouracil/oxaliplatin chemotherapy. Results Among all assessed, those possessing P = 0.019; log-rank test). Also, GC genotype increased relative risk time progression that was 1.55 (95% CI, 0.8–3.0) times homozygous GG ( 0.17; Conclusion Overall, our data suggest active may be platinum-based